Welcome to epgonline.org - the website for healthcare professionals

What's new?

  • ,Whats New LAL-D

    Launch of LAL-D Knowledge Centre

    A new educational resource on lysosomal acid lipase deficiency is
    now available to epgonline.org users. Content highlights include latest
    disease awareness facts and statistics, important treatment information and
    a video channel comprising expert discussions on topics such
    as diagnostic approach and current prognosis.

  • ,CSU news case studies 2016

    Updates to the Chronic Spontaneous
    Urticaria Knowledge Centre

    Case studies from urticaria experts Professor Christian Vestergaard
    and Professor Torsten Zuberbier have been added to the ‘Case Studies
    section of the Chronic Spontaneous Urticaria Knowledge Centre.
    Additionally, this resource has been updated with information
    on the TARGET My Hives app and refreshed with a whole new look and feel.

  • ,OAC Reversal Whats New 2

    Launch of Oral Anticoagulation Reversal Knowledge Centre

    This new resource provides healthcare professionals with accurate information on the approaches
    to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding,
    or require surgery. View illustrated and referenced sections on management of bleeding, oral
    anticoagulants, symposium highlights, key publications commentary and more. This resource is
    developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with
    content provided by CSL Behring.

    This resource is not intended for healthcare professionals outside Europe.

  • ,Hypogonadism Relaunch Whats New

    Launch of updated Hypogonadism Knowledge Centre

    Our Hypogonadism Knowledge Centre contains important disease awareness
    information to support healthcare professionals in the current best practice
    treatment and management of male hypogonadism and is available to access free of
    charge. Sections cover epidemiology, pathophysiology, signs and symptoms, treatment
    options, as well as useful resources and a regularly updated publications digest.

    G.MKT.GM.MH.01.2016.0364

  • ,Cystic Fibrosis Knowledge Centre

    Launch of the Cystic Fibrosis Knowledge Centre

    This new resource has been developed to support healthcare professionals
    in the treatment of patients with cystic fibrosis (CF).
    It contains a host of clinical information including a disease awareness section,
    emerging and supportive therapeutic options and current best practice
    based on recently updated guidelines by the
    European Cystic Fibrosis Society (ECFS).

Latest News

AstraZeneca announces positive results of REPROVE trial of Zavicefta (ceftazidime-avibactam)to treat hospital infections, including ventilator-associated pneumonia.

23-Jul-2016

AstraZeneca announced positive results from the Phase III REPROVE trial for Zavicefta (ceftazidime-avibactam), a new combination antibiotic for the treatment of a broad range of serious Gram-negative bacterial infections in hospitalised patients. ...

NICE does not recommend Tagrisso (osimertinib) to treat T790M resistance mutation NSCLC.-AstarZeneca

23-Jul-2016

The National Institute for Health and Care Excellence (NICE), has in a preliminary report not recommended Tagrisso (osimertinib)to treat a subset of patients with T790M resistance mutation, non-small cell lung cancer, as it is not cost effective ...

AMG 785 (romosozumab) filed with the FDA for osteoporosis in postmenopausal women at increased risk of fracture- Amgen and UCB

23-Jul-2016

Amgen and UCB have announced the submission of a Biologics License Application (BLA) to the FDA for AMG 785 (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. ...

EU CHMP recommends approval of Kisplyx (lenvatinib) plus everolimus for treatment of adults with advanced renal cell carcinoma- Eisai/Novartis

23-Jul-2016

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Kisplyx (lenvatinib) in combination with everolimus, from Eisai/Novartis, for the treatment of adult patients with advanced renal cell ...

Five year data for Argus II Retinal Prosthesis System shows improvement in vision with retinitis pigmentosa- Second Sight Medical

23-Jul-2016

Second Sight Medical has announced positive five-year outcomes associated with patients using the Argus II Retinal Prosthesis System. The Argus II captures images on an eyeglass-mounted miniature video camera, converts the images to electrical ...

EU CHMP recommends approval of Cabometyx (cabozantinib) as monotherapy for advanced renal cell carcinoma- Ipsen Pharma

23-Jul-2016

The EU CHMP recommended granting marketing authorisations for Cabometyx (cabozantinib), from Ipsen Pharma, as monotherapy for the treatment of advanced renal cell carcinoma (kidney cancer). Cabometyx will be available as 20 mg, 40 mg and 60 mg ...

The Prescription Drug User Fee Act (PDUFA) goal date for bezlotoxumab a treatment for Clostridium difficile is extended to 23 October 2016.- Merck Inc.

23-Jul-2016

MerckInc., said that the FDA has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application (BLA) for bezlotoxumab, an investigational agent ...

Recent Updates

Drugs

Clinical Guidelines

2016 European Guidelines on cardiovascular disease prevention in clinical practice

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

EASL Clinical Practice Guidelines on the management of benign liver tumours

EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones

Medical Journals

Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.

Hypothyroidism and obesity: An intriguing link.

Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.

Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.

epgonline.org Social

Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors